NeoPharm maintained at buy by Merrill

Merrill Lynch analyst David Munno kept NeoPharm, Inc. at its buy rating on news that the Precise trial is likely to continue to final analysis, with interim data due in the June 19 week. The analyst believes the trial has a better chance of meeting its final endpoint rather than the interim endpoint and projects peak sales of $225 million. Shares of the Waukegan, Ill.-based biopharmaceutical company were down 20 cents, or 2.91%, at $6.68 on volume of 916,773 shares versus the three-month running average of 299,686 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.